GTS Securities’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-19,027
Closed -$996K 1795
2026
Q1
$996K Buy
+19,027
New +$968K 0.04% 400
2025
Q4
Sell
-38,376
Closed -$1.49M 1733
2025
Q3
$1.49M Sell
38,376
-28,251
-42% -$971K 0.06% 285
2025
Q2
$2M Buy
66,627
+41,739
+168% +$1.19M 0.09% 178
2025
Q1
$710K Sell
24,888
-16,983
-41% -$537K 0.03% 534
2024
Q4
$1.38M Buy
+41,871
New +$1.58M 0.07% 228
2024
Q2
Sell
-9,154
Closed -$327K 4269
2024
Q1
$327K Sell
9,154
-8,738
-49% -$303K ﹤0.01% 2922
2023
Q4
$589K Sell
17,892
-272
-1% -$7.3K ﹤0.01% 2652
2023
Q3
$494K Buy
18,164
+7,712
+74% +$232K ﹤0.01% 2639
2023
Q2
$330K Buy
+10,452
New +$325K 0.01% 837

Other funds holding SBIO

GTS Securities's SBIO Position: Q2 2026 in Review

GTS Securities sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q2 2026, closing a stake of 19,027 shares — an estimated $996K sold.

GTS Securities first reported a position in SBIO in Q2 2023 and held it in 9 quarters. The position peaked at $2M in Q2 2025. 66 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

  • GTS Securities reported no remaining ALPS Medical Breakthroughs ETF position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 19,027 ALPS Medical Breakthroughs ETF shares in Q2 2026, an estimated $996K.
  • GTS Securities first reported a position in ALPS Medical Breakthroughs ETF in Q2 2023 and held it in 9 quarters.
  • GTS Securities's ALPS Medical Breakthroughs ETF position peaked at $2M in Q2 2025.
  • 66 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.